Latest news and insights on the pharmaceutical industry | Indian Pharma Post | Page 389

Results For "EY"

3999 News Found

NPPA monitors and caps prices of essential drugs: Mandaviya
Policy | August 03, 2021

NPPA monitors and caps prices of essential drugs: Mandaviya

NPPA has capped the trade margin for Oxygen Concentrators at 70% on Price to Distributor (PTD) level


Meddo acquires Doxper in a cash and stock deal
Healthcare | August 03, 2021

Meddo acquires Doxper in a cash and stock deal

This deal makes Meddo, one of the largest health-tech players in India


API exports surpass imports by value in 2020-21
Policy | August 03, 2021

API exports surpass imports by value in 2020-21

The govt has rolled out three schemes for promoting the manufacture of API


AYUSH 64 effective in mild and moderate COVID 19
Drug Approval | August 03, 2021

AYUSH 64 effective in mild and moderate COVID 19

It works as an adjunct to standard care based on robust clinical trials


Glenmark signs agreement with SaNOtize to manufacture NONS
News | August 02, 2021

Glenmark signs agreement with SaNOtize to manufacture NONS

The Phase III clinical trial for NONS is expected to be completed by Q4 2021.


Ajanta Pharma aims to file 10-12 ANDAs per annum
News | August 02, 2021

Ajanta Pharma aims to file 10-12 ANDAs per annum

India business is growing as per projections; whereas US business will bounce back soon.


Granules India earmarks Rs 400 crore as Capex for FY 22
News | August 02, 2021

Granules India earmarks Rs 400 crore as Capex for FY 22

The company has an outlay of Rs 120-140 crore as R & D expense for FY 22


Clinical trials in the UK to study the efficacy of Ashwagandha on COVID 19 patients
Drug Approval | August 02, 2021

Clinical trials in the UK to study the efficacy of Ashwagandha on COVID 19 patients

Ayush Ministry will conduct the study along with the UK’s London School of Hygiene and Tropical Medicine


Krsnaa Diagnostics public issue opens from Aug 4-6th 2021
Healthcare | August 02, 2021

Krsnaa Diagnostics public issue opens from Aug 4-6th 2021

Price band in the range of Rs 933 to Rs 954


Zydus Wellness Q1FY22 consolidated net profit at Rs. 130.80 Cr
News | July 31, 2021

Zydus Wellness Q1FY22 consolidated net profit at Rs. 130.80 Cr

The company posted net profit of Rs.89.20 crores for the period ended June 30, 2020.